Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status
Open Access
- 1 March 1993
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 67 (3), 606-611
- https://doi.org/10.1038/bjc.1993.111
Abstract
This study aimed to investigate the effect of tamoxifen on breast tumour levels of oestrogen and progesterone receptor (ER and PR) and proliferation as defined by the Ki67 antibody. A group of primary breast cancer patients was randomised to receive either tamoxifen (n = 59) or placebo (n = 44) treatment in the interval between clinic and surgery (median 21 days). Frozen sections of breast tumour biopsies obtained before and after treatment were stained immunocytochemically to obtain the percentage of nuclei containing ER and PR, and a Ki67 labelling index (LI). Tamoxifen-treated patients had a median Ki67 LI of 5.6% in the first biopsy falling to 3.0% in the second biopsy (P < 0.001 by Wilcoxon's matched pairs test), whereas placebo-treated patients had a median Ki67 LI of 5.4% in the first biopsy and 5.75% in the second (no significant difference). No significant differences were observed when the median %ER or %PR staining before and after treatment were compared. The Ki67 LI tended to increase with increasing histological grade and was greater in tumours that were ER - ve compared to those that were ER + ve (> 5% nuclei stained), median 7.8% and 4.3% respectively (P = 0.011 by Mann-Whitney U-test). However, the decline in tumour Ki67 LI following anti-oestrogen treatment failed to correlate with ER and PR status or to predict recurrence over a short follow-up period. To our knowledge, this is the first time that tamoxifen treatment has been shown to reduce the Ki67 LI in human breast tumours in vivo. These data indicate that staining with the Ki67 antibody may be useful in monitoring response to anti-oestrogen therapy.Keywords
This publication has 30 references indexed in Scilit:
- Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variablesThe Journal of Pathology, 1987
- Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breastCancer, 1987
- ENDOCRINE THERAPY FOR ADVANCED-CARCINOMA OF THE BREAST - EFFECT OF TUMOR HETEROGENEITY AND SITE OF BIOPSY ON THE PREDICTIVE VALUE OF PROGESTERONE-RECEPTOR ESTIMATIONS1987
- ENDOCRINE THERAPY FOR ADVANCED-CARCINOMA OF THE BREAST - RELATIONSHIP BETWEEN THE EFFECT OF TAMOXIFEN UPON CONCENTRATIONS OF PROGESTERONE-RECEPTOR AND SUBSEQUENT RESPONSE TO TREATMENT1987
- The correlation of growth fractions with histologic grading and lymph node status in human mammary carcinomaCancer, 1987
- Intermediate estrogen receptor levels in breast cancerEuropean Journal of Cancer and Clinical Oncology, 1986
- Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67.Journal of Clinical Pathology, 1986
- BREAST-CARCINOMA CELL-KINETICS, MORPHOLOGY, STAGE, AND HOST CHARACTERISTICS - A THYMIDINE LABELING STUDY1986
- Heterogeneity in hormone receptor status in primary and metastatic breast cancer.1985
- VARIATION OF ESTROGEN AND PROGESTERONE-RECEPTOR STATUS IN BREAST-CANCER1985